Navigation Links
Valeant Pharmaceuticals Reports Fourth Quarter and Full Year Financial Results
Date:2/24/2009

y.

Research and development costs decreased 60% to $11.9 million in the 2008 fourth quarter as compared to $29.4 million reported in the same period in 2007. This decrease is due to the effect of the GSK collaboration, as well as cost reduction efforts by the company. Under collaboration accounting R&D spending in the quarter on the collaboration was offset by a credit from the initial upfront payment.

In the fourth quarter, the company recorded purchased in-process research and development charges of $186.3 million, related primarily to the previously announced acquisition of Dow Pharmaceutical Sciences, Inc. The company also recorded restructuring, asset impairment and disposition expenses of $17.0 million in the quarter.

Loss from continuing operations was $150.5 million for the fourth quarter of 2008, or a loss of $1.82 per diluted share as compared to income from continuing operations of $2.1 million, or $0.02 per diluted share for the fourth quarter of 2007. Valeant intends to continue to buy assets in the future, which means that company financials will be subject to certain adjustments for purchase accounting that could significantly change GAAP EPS. Valeant believes that excluding these adjustments, such as acquired in-process research and development (IPR&D), restructuring, asset impairments and dispositions, amortization expense, gain on early extinguishment of debt and the tax effect of such changes, facilitates investors' understanding of the trends in the company's underlying business. Therefore, the company uses a Cash EPS metric to evaluate company financial performance. On a non-GAAP basis, or Cash EPS basis, adjusted income from continuing operations was $43.2 million or $0.52 per diluted share in the fourth quarter of 2008 as compared to adjusted income from continuing operations of $25.1 million, or $0.28 per diluted share in the fourth quarter of 2007. For the full 2
'/>"/>

SOURCE Valeant Pharmaceuticals International
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related medicine news :

1. Three Rivers Pharmaceuticals(R), LLC Acquires Hepatitis C Drug Infergen(R) from Valeant Pharmaceuticals
2. Valeant Pharmaceuticals to Announce 2008 Fourth Quarter and Year Results on February 24, 2009
3. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
4. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
5. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
6. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
7. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
8. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
9. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
10. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
11. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/21/2014)... To accommodate the ever-growing customer base, Angeldress.co.uk decided to ... Recently, the company has unveiled its 2014 vintage ... wedding gowns, Angeldress.co.uk wants to make sure that all ... way. Its high quality vintage wedding outfits are now ... 62% off. , Online shopping is becoming more and ...
(Date:9/21/2014)... September 21, 2014 “Cluster headaches are ... intense and difficult to resolve,” said Steve Young of ... think of a pain that is more intense.” , ... from cluster headaches, or migraines, that medical research is ... serotonin system,” he added. , Serotonin (5-HT, 5-hydroxytryptamine) is ...
(Date:9/21/2014)... C8 lawsuits move forward in the U.S. ... of 20 possible C8 lawsuits selected for bellwether ... Wright & Schulte LLC. Court records show these six ... lawsuits filed that represent individuals who purportedly developed kidney ... of being exposed to water contaminated by the C8 ...
(Date:9/20/2014)... Recently, UWDress.com, a professional company of women’s dresses ... newly announced evening cocktail dresses . As a ... outfits are very popular among worldwide customers. Now, all ... (up to 65 percent off). , All UWDress.com’s ... occasion outfits for the global clients. The company is ...
(Date:9/20/2014)... (PRWEB) September 20, 2014 David Cooke ... 2014. The first poster looked at the clinical benefits ... cycle for calculating diastolic function. In conjunction with colleagues ... renal disease and normal LVEF by echo (>50%). Each ... protocol, and standard SPECT. Emory Toolbox 4.0 ...
Breaking Medicine News(10 mins):Health News:Angeldress.co.uk Launches New Range Of 2014 Vintage Wedding Dresses In Its Online Store 2Health News:Homeostasis: Equinox Serotonin (5HT) Headache Stories ~ New on the Bryan William Brickner Blog 2Health News:C8 Lawsuit Claims Move Forward as Six Possible Cases for Bellwether Trials Selected in DuPont Water Contamination Lawsuits, Reports Wright & Schulte LLC 2Health News:C8 Lawsuit Claims Move Forward as Six Possible Cases for Bellwether Trials Selected in DuPont Water Contamination Lawsuits, Reports Wright & Schulte LLC 3Health News:C8 Lawsuit Claims Move Forward as Six Possible Cases for Bellwether Trials Selected in DuPont Water Contamination Lawsuits, Reports Wright & Schulte LLC 4Health News:Cheap Evening Cocktail Dresses Recently Introduced At UWDress.com 2Health News:Versatility of Emory Toolbox 4.0 Shown at ASNC in Scientific Posters 2Health News:Versatility of Emory Toolbox 4.0 Shown at ASNC in Scientific Posters 3
... Jenifer Goodwin HealthDay Reporter , MONDAY, Aug. ... marijuana, reduced pain in patients with nerve pain stemming ... Twenty-one adults with chronic nerve pain were taught to ... through a pipe, three times a day, for five ...
... When given a choice, older people prefer to read negative news, ... In fact, older readers who chose to read negative stories ... according to the results. And what about younger people? Well, ... results come from a study of 276 Germans who were asked ...
... growing epidemic of the world,s most common heart rhythm ... admissions in Australia, according to cardiology researchers. A ... University of Adelaide and the Cardiovascular Research Centre at ... to atrial fibrillation had more than tripled in Australia ...
... Children,s Hospital finds visits to emergency departments for concussions ... over a 10-year period, and appear to be highest ... concussions is highest in high school-aged athletes, but the ... study is published in the September 2010 issue of ...
... By Jenifer Goodwin HealthDay Reporter , SUNDAY, ... a gene on chromosome 8 may raise the risk of ... been believed to have a genetic component, pinpointing specific genes ... is among the first to identify a specific genetic variant ...
... who will develop tuberculosis, as scientists have identified changes ... are from an international study published in the August ... doctors and researchers at Nationwide Children,s Hospital using blood ... is caused by the bacterium Mycobacterium tuberculosis, which usually ...
Cached Medicine News:Health News:Smoked Marijuana May Ease Chronic Nerve Pain 2Health News:Smoked Marijuana May Ease Chronic Nerve Pain 3Health News:Over 50? You probably prefer negative stories about young people 2Health News:Over 50? You probably prefer negative stories about young people 3Health News:Heart disorder hits national epidemic proportions 2Health News:Concussions in young athletes on the rise 2Health News:Concussions in young athletes on the rise 3Health News:New Migraine Gene Discovered 2Health News:New Migraine Gene Discovered 3Health News:New genomic marker for tuberculosis may help identify patients who will develop the disease 2Health News:New genomic marker for tuberculosis may help identify patients who will develop the disease 3
(Date:9/19/2014)... CHICAGO, Ill. , Sept. 19, 2014  The ... ABBV ) declared a quarterly cash dividend of $0.42 ... payable Nov. 17, 2014 to stockholders of record at ... About AbbVie AbbVie is a global, research-based biopharmaceutical ... company,s mission is to use its expertise, dedicated people ...
(Date:9/19/2014)... STATION, N.J. , Sept. 19, 2014 Merck (NYSE: ... United States and Canada , is ... Desafiando La Diabetes: Logra Tus Metas , an educational program ... their blood sugar -- a key treatment goal to help reduce ... United States are at a higher risk for developing ...
(Date:9/19/2014)... 2014 Larry J. Merlo , President and ... speak before the National Press Club in Washington, ... move to stop selling tobacco products and its leadership in ... "Dramatic changes in our health care system pose ... Merlo has said. "CVS Health has a truly unique combination ...
Breaking Medicine Technology:Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 2Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 3Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 4Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 5CVS Health CEO to Address National Press Club on Landmark Decision to Quit Tobacco, Leadership in Health Care Innovation 2CVS Health CEO to Address National Press Club on Landmark Decision to Quit Tobacco, Leadership in Health Care Innovation 3
... PASADENA, Calif.--(BUSINESS WIRE)--Jun 20, 2007 - Materia, ... licensing of its,metathesis platform to Eisai Co., ... in drug discovery and development.,The non-exclusive license ... pharmaceutical compounds and related processes,using the Company's ...
... 2007 - VIVUS, Inc.,(NASDAQ: VVUS), a pharmaceutical ... novel therapeutic products,announced that Abstract #2209-PO, Evaluation ... with Phentermine and Topiramate:,Outcomes in a Private ... Diabetes Association 2007 Scientific Sessions Abstract,book. The ...
Cached Medicine Technology:Materia Licenses Metathesis Catalyst Platform to Eisai 2VIVUS Announces Abstract Published at American Diabetes Association,Scientific Sessions 2VIVUS Announces Abstract Published at American Diabetes Association,Scientific Sessions 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: